Matthew Galsky, MD Email Matthew Galsky
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Urology
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
Dr. Galsky is Professor of Medicine, Director of Genitourinary Medical Oncology, Director of the Novel Therapeutics Unit, and Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. He is a member of the Cancer Clinical Investigation Program for The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches. Dr. Galsky serves on the Cancer Immunotherapy Guidelines – Bladder Task Force for the Society for Immunotherapy of Cancer. He is also an advisor on bladder cancer for the Society of Urologic Oncology Clinical Trials Consortium and Co-chair of the Genitourinary Clinical Trial Working Group for the Hoosier Cancer Research Network.
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Cancer
- Testicular Tumors
- Urologic Cancers
MD, Tufts University School of Medicine
Residency, Internal Medicine
Beth Israel Deaconess Medical Center- Harvard Medical School
Fellowship, Medical Oncology
Memorial Sloan-Kettering Cancer Center
American Society of Clinical Oncology Merit Award
Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)
Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
Alpha Omega Alpha Honor Society
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Galsky during 2019 and/or 2020. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Astellas Pharma Inc.
- Bristol-Myers Squibb
- EMD Serono, Inc. (Merck & Co., Inc.)
- Eli Lilly and Company
- Incyte Corporation
- Pfizer Inc.
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Rappta Therapeutics
Scientific Advisory Board:
- Astellas Pharma Inc.
- Dragonfly Therapeutics
- Genentech, Inc.
- Janssen Pharmaceuticals, Inc.
- Merck & Co., Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.